Minerva Neurosciences, Inc. NERV
We take great care to ensure that the data presented and summarized in this overview for Minerva Neurosciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NERV
View all-
Federated Hermes, Inc. Pittsburgh, PA1.35MShares$3.05 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA252KShares$569,6550.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny157KShares$355,2710.0% of portfolio
-
Ubs Oconnor LLC Chicago, IL107KShares$242,3980.02% of portfolio
-
Black Rock Inc. New York, NY72.7KShares$164,2310.0% of portfolio
-
Geode Capital Management, LLC Boston, MA56.5KShares$127,5900.0% of portfolio
-
Northern Trust Corp Chicago, IL23KShares$52,0900.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA20.2KShares$45,7060.0% of portfolio
-
Acadian Asset Management LLC Boston, MA17.4KShares$39,3600.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il17.2KShares$38,9600.0% of portfolio
Latest Institutional Activity in NERV
Top Purchases
Top Sells
About NERV
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Insider Transactions at NERV
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 02
2023
|
Remy Luthringer CEO |
SELL
Open market or private sale
|
Direct |
3,641
-5.01%
|
$10,923
$3.76 P/Share
|
|
May 01
2023
|
Remy Luthringer CEO |
SELL
Open market or private sale
|
Direct |
23,753
-24.64%
|
$71,259
$3.85 P/Share
|
|
May 01
2023
|
Frederick W Ahlholm SVP, CFO and Secretary |
SELL
Open market or private sale
|
Direct |
3,580
-16.97%
|
$14,320
$4.48 P/Share
|
|
May 01
2023
|
Geoff Race President |
SELL
Open market or private sale
|
Direct |
22,082
-30.08%
|
$66,246
$3.85 P/Share
|
|
Apr 28
2023
|
Remy Luthringer CEO |
BUY
Grant, award, or other acquisition
|
Direct |
88,077
+47.75%
|
-
|
|
Apr 28
2023
|
Frederick W Ahlholm SVP, CFO and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
19,843
+48.47%
|
-
|
|
Apr 28
2023
|
Geoff Race President |
BUY
Grant, award, or other acquisition
|
Direct |
46,987
+39.03%
|
-
|
|
Dec 01
2021
|
David Kupfer |
SELL
Open market or private sale
|
Direct |
55,635
-25.38%
|
$0
$0.88 P/Share
|
|
Dec 16
2020
|
Frederick W Ahlholm SVP, CFO and Secretary |
SELL
Open market or private sale
|
Direct |
1,845
-15.53%
|
$3,690
$2.64 P/Share
|
|
Dec 16
2020
|
Remy Luthringer CEO |
SELL
Open market or private sale
|
Direct |
1,300
-1.92%
|
$2,600
$2.64 P/Share
|
|
Dec 16
2020
|
Geoff Race President |
SELL
Open market or private sale
|
Direct |
6,190
-2.85%
|
$12,380
$2.64 P/Share
|
|
Dec 16
2020
|
Joseph H. Reilly SVP & Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,228
-9.23%
|
$6,456
$2.64 P/Share
|
|
Dec 14
2020
|
Frederick W Ahlholm SVP, CFO and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+29.61%
|
-
|
|
Dec 14
2020
|
Remy Luthringer CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
18,750
+21.67%
|
-
|
|
Dec 14
2020
|
Geoff Race President |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+5.43%
|
-
|
|
Dec 14
2020
|
Joseph H. Reilly SVP & Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,750
+20.01%
|
-
|
|
Jun 24
2019
|
Index Venture Associates Iii LTD > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
197,000
-4.81%
|
$1,182,000
$6.01 P/Share
|
|
Jun 20
2019
|
Index Venture Associates Iii LTD > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
33,575
-0.81%
|
$134,300
$4.34 P/Share
|
|
Jun 19
2019
|
Index Venture Associates Iii LTD > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
77,243
-1.84%
|
$308,972
$4.44 P/Share
|
|
Jun 18
2019
|
Index Venture Associates Iii LTD > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
49,675
-1.17%
|
$198,700
$4.44 P/Share
|